• Increase
  • Decrease
  • Normal

Current Size: 100%

IWMF Publications

IWMF volunteers, volunteers from the IWMF Affiliates, and WM researchers  develop publications including Booklets, Treatment Guides, and Facts Sheets to provide the newly diagnosed and veteran patients, as well as their caregivers, with up-to-date information about Waldenstrom's macroglobulinemia and how to treat it.

The IWMF does not warranty the content of these publications. We are making these available to you as information, and we encourage you to discuss what may be appropriate to you with your hematologist/oncologist.

To download publication(s) please click on the appropriate below.

Booklets

Title and Description English Traditional Chinese
繁體中文
Simplified Chinese 简体中文 Deutsch Espanol Francais Italiano

Basic Immunology

By Guy Sherwood, M.D., 2014
A comprehensive review of immunology as it relates to WM.

Glossary and Abbreviations

Written & compiled by Guy Sherwood, M.D., Bret Blakeslee, Sue Herms, & Peter DeNardis, 2015.
This glossary is designed to help patients with WM learn and understand pertinent medical terms that relate to our disease.

Medical Tests

By Guy Sherwood, M.D., 2007. Revised by Sue Herms and Linda Nelson, 2016.
A reference booklet of medical terms and tests, this revision places particular emphasis on expanding the explanation of the Complete Blood Count and on Immunoglobulins. Tests for beta-2 microglobulin and light chains have been added, as has genetics testing.

Questions and Answers

Q&A cover

Revised 2010/2014 Guy Sherwood and Sue Herms
Revised 2017 Sue Herms and Linda Nelson

Designed to address common questions about Waldenstrom’s macroglobulinemia, this booklet, including a full glossary of terms, is a detailed companion to the IWMF webpage, Frequently Asked Questions (FAQ).

Clinical Practice Guide for the Treatment of WM (Australia)

By Dipti Talaulikar, M.D., Constantine Tam, M.D., et al, 2016

This booklet is a consensus established by the Australian Medical Scientific Advisory Group, which consists of a panel of haematologists across Australia, and it is provided by  the IWMF Affiliate (WMozzies) in Australia.

Guide to WM (Germany)

By Christian Buske, M.D., and George Hess, M.D., 2014.
This booklet is provided by the IWMF-Affiliate Morbus Waldenstrom (MOWA) in Germany.

Guide to WM and LPL (UK)

By Shirley D'Sa, M.D., 2014, updated 2017.
This booklet is provided by the IWMF Affiliate Waldenstrom's UK (WMUK). The drugs mentioned in the booklet are noted by their generic names and by their UK-specific trade names and may/may not be available in UK/US (or elsewhere) unless in the context of a clinical trial.

Treatment Options Guides

These Treatment Options Guides review drug therapies and treatment guidelines currently used in the management of Waldenstrom's macroglobulinemia. They are designed to provide patients with some of the necessary information to allow them to participate with their physicians in determining the best course of treatment for their disease.

Title and Description English Traditional Chinese
繁體中文
Simplified Chinese 简体中文 Deutsch Espanol Francais Italiano

Alkylating Agents and Nucleoside Analogs

By Suzanne Herms, 2016

This Guide discusses alkylating agents, such as chlorambucil (Leukeran), cyclophosphamide (Cytoxan), melphalan (Alkeran) and bendamustine (Bendeka, Treanda, Levact), as well as nucleoside analogs, such as fludarabine (Fludara) and cladribine (2CdA or Leustatin).

Corticosteroids and Immunomodulators

By Suzanne Herms, 2016

This Guide includes corticosteroids, such as prednisone, prednisolone, and dexamethasone, as well as immunomodulators (IMiDs), such as thalidomide (Thalomid), lenalidomide (Revlimid), and pomalidamide (Actimid or Pomalyst).

Monoclonal Antibodies

By Suzanne Herms, 2016

This Guide discusses monoclonal antibodies, such as rituximab (Rituxan or Mabthera), ofatumumab (Arzerra), and alemtuzumab (Campath).

Proteasome Inhibitors

By Suzanne Herms, 2016

This Guide includes proteasome inhibitors, such as bortezomib (Velcade), carfilzomib (Kyprolis), and ixazomib (Ninlaro).

Targeted Therapies/Pathway Inhibitors

By Suzanne Herms, 2016

This Guide discusses targeted therapies/pathway inhibitors to B-cell signaling, such as ibrutinib (Imbruvica) and everolimus (RAD001 or Afinitor).

Fact Sheets

These are short summaries that include information about WM and discuss several common treatments for it.

Topic English Traditional Chinese
繁體中文
Simplified Chinese
简体中文
Deutsch Espanol Francais Italiano Norsk
About Waldenstrom's Macroglobulinemia - Highlights
About WM – Details
Bendamustine
Decoding Drug Names
Ibrutinib
Plasmapheresis
Rituxan
Stem Cell Transplantation
Velcade

Section: 
Google Adwords: